Therapy Detail

Therapy Name LY2874455
Therapy Description

LY2874455, a pan-FGFR inhibitor, has equivalent potency against FGFR1-4 and inhibits FGF/FGFR mediated signaling to reduce tumor growth (PMID: 21900693).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LY2874455 FGFR Inhibitor (Pan) 17 LY2874455, a pan-FGFR inhibitor, has equivalent potency against FGFR1-4 and inhibits FGF/FGFR mediated signaling to reduce tumor growth (PMID: 21900693).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR3 N540K Advanced Solid Tumor decreased response LY2874455 Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880). 28034880
FGFR3-TACC3 urinary bladder cancer sensitive LY2874455 Preclinical Actionable In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443). 21900693 23175443
Unknown unknown stomach cancer not applicable LY2874455 Phase I Actionable In a Phase I trial, gastric cancer patients treated with LY2874455 demonstrated some efficacy, including one patient with a partial response, 12 patients with stable disease after two cycles, and 4 patients with stable disease after four cycles of treatment, and had a median progression free survival of 62 days (PMID: 28589492). 28589492
FGFR3 L608V Advanced Solid Tumor sensitive LY2874455 Preclinical - Cell culture Actionable In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). 28034880
Unknown unknown non-small cell lung carcinoma not applicable LY2874455 Phase I Actionable In a Phase I trial, 92% (11/12) of patients with non-small cell lung carcinoma demonstrated stable disease after two cycles of LY2874455, however, after four cycles, all patients had either progressed or discontinued the study (PMID: 28589492; NCT01212107). 28589492
FGFR3 over exp Advanced Solid Tumor sensitive LY2874455 Preclinical Actionable In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693). 21900693
FGFR3 V555M Advanced Solid Tumor sensitive LY2874455 Preclinical - Cell culture Actionable In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880). 28034880
FGFR3 K650E Advanced Solid Tumor sensitive LY2874455 Preclinical - Cell culture Actionable In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880). 28034880
Unknown unknown thyroid cancer not applicable LY2874455 Phase I Actionable In a Phase I trial, a patient with thyroid cancer demonstrated stable disease when treated with LY2874455 (PMID: 28589492). 28589492
Clinical Trial Phase Therapies Title Recruitment Status